bbc_business

Amsterdam bans public adverts for meat and fossil fuels

amsterdam became the first capital city to ban public ads for meat and fossil fuel products on 1 may. billboards, tram shelters, and metro stations now show the rijksmuseum and piano concerts instead of chicken nuggets, suvs, and budget flights.

the ban covers burgers, petrol cars, and airlines. meat was a tiny slice of outdoor ad spend — roughly 0.1% — versus about 4% for fossil-related products. politicians say it aligns streetscape with the city's goal of carbon neutrality by 2050 and halving meat consumption by then.

haarlem was first in the world to ban most meat ads in public spaces back in 2022, with the ban taking effect in 2024 alongside a fossil fuel ad ban. utrecht and nijmegen have followed. globally, edinburgh, sheffield, stockholm, and florence restrict fossil-fuel ads; france has a nationwide ban. there's no direct evidence yet that removing meat ads shifts diets, but researchers call amsterdam's move a "fantastic natural experiment."

source: bbc_business
sentiment: +0.00 · impact: 0.20

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

oil started the week higher on a disputed claim of an iranian strike on a u.s. navy ship in the strait of hormuz. the report, which hasn't been confirmed by u.s. officials, added fresh volatility to crude markets. the strait of hormuz is a key chokepoint

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

source: marketwatch_top sentiment: -0.70 · impact: 0.80

Warsh's take on Fed independence is met with confusion and some concern

kevin warsh, trump's pick to lead the fed, is drawing confusion from six former fed officials over his views on fed independence. the sticking point: he draws a line between monetary policy — which he says should be "strictly independent" — and "non-monetary matters" like international

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

the weight-loss and diabetes drug boom is creating a bubble risk for pharma, according to a deloitte report out monday. r&d returns for the top 20 pharma companies hit 7% for a third straight year, driven almost entirely by glp-1 drugs like wegovy and zepbound. strip those out

Read more

Oil prices climb after disputed report of Iran strike on U.S. warship in the Strait of Hormuz

The markets are in the early stages of pricing in stagflation. Here’s what happens next.

Warsh's take on Fed independence is met with confusion and some concern

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds